In the current study, we aimed to gain insight into mechanistic aspects of cilofexor and to evaluate the potential anti-cholestatic, anti-inflammatory and anti-fibrotic effects driven by FXR agonism in the Mdr2-/- mouse, an established model of sclerosing cholangitis. This evidence concerns the gene NR1H4 and sclerosing cholangitis.